India needs policy predictability to speed up drug approvals and boost pharma innovation: OPPI DG

Anil Matai from the Organisation of Pharmaceutical Producers of India emphasized the need for regulatory predictability. He noted that India's clinical trials need improvement to match faster approvals seen in China. While India excels as a generi...

India is still at an early stage when it comes to clinical trials and needs a more predictable regulatory environment to speed up drug approvals and encourage pharmaceutical innovation, a senior industry official said on Wednesday.

Anil Matai, Director General of the Organisation of Pharmaceutical Producers of India (OPPI), also cautioned against frequent use of the extraordinary powers under Para 19 of the Drugs (Prices Control) Order (DPCO), 2013, saying such interventions could affect industry sentiment.

Para 19 allows the government and the National Pharmaceutical Pricing Authority (NPPA) to fix or revise the ceiling or retail price of any drug in the public interest.


Speaking to PTI, Matai said pharmaceutical companies needed greater consistency in regulatory requirements, approval processes and timelines to plan investments and bring new medicines to the market.

"We need better predictability on regulations, pricing and innovation. Speed and predictability have to be our focus," he said.

Pointing to China's progress, Matai said India and China were at a comparable stage in biologics about a decade ago, but China had since pulled considerably ahead.
ADVERTISEMENT

"India and China were around the same level in biologics even a decade back, but now they have moved miles ahead... India is at a nascent stage in clinical trials and approvals take a long time. This needs to change urgently," he said.

Matai said India had built its reputation as the world's generic pharmacy over the past 25 years, but the next phase of growth would have to come from innovation.

India is the world's third-largest pharmaceutical producer by volume but ranks 11th by value, reflecting the industry's relatively smaller presence in higher-value segments.

According to Matai, Indian pharmaceutical companies should build on their strengths in quality and manufacturing rather than continue competing largely on price.
ADVERTISEMENT

"The world is looking at India as a generic pharmacy, and not as a pharmacy, and that, too, needs to change," he said.

He also emphasised that generic and innovative medicines should have room to grow alongside each other in the Indian market.
ADVERTISEMENT

Even as companies expand their innovative drug portfolios, Matai estimated that generics would continue to make up 80-85% of the market, with innovative medicines accounting for the remaining 15%.

On trade margin rationalisation (TMR) for anti-cancer drugs, Matai welcomed the move, saying it could help make treatment more affordable for patients.

He said there was a particularly strong case for reviewing trade margins on oncology medicines and other expensive drugs, where high margins can add substantially to the cost borne by patients.

At the same time, he cautioned that any changes should take into account their impact on pharmaceutical companies' profitability and future investments.

"Principally we are for TMR, for all high-price drugs. So long as it doesn't impact the industry per se in terms of their profitability because otherwise their investments would come down," he added.
READ MORE
ADVERTISEMENT

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

More from our Partners

Loading next story
Business News › Industry › Healthcare/Biotech › Pharmaceuticals › India needs policy predictability to speed up drug approvals and boost pharma innovation: OPPI DG
Text Size:AAA
Success
This article has been saved

*

+